HONG KONG, March 11, 2026 /PRNewswire/ — The “Sun Life ‘The Big Bounce’ World Tour – Hong Kong,” a 17-day family-friendly extravaganza at the Great Lawn of the Art Park in the West Kowloon Cultural District, came to a successful and joyous conclusion on February 22. Title-sponsored by Sun Life, ‘The Big Bounce’ spanned the Chinese New Year period and proved immensely popular among families, with interactive performances, musical elements, and anime‑themed installations being key highlights that added to the vibrant atmosphere.

This year, Sun Life partnered with Yan Chai Hospital to invite hundreds of students and parents from its affiliated kindergartens and childcare centers to be among the first to experience the bouncing extravaganza, underscoring the theme of “family togetherness and joy”. In celebration of Sun Life’s journey towards its 135th anniversary in Hong Kong next year, on February 22, it distributed delightful gifts to participants at the West Kowloon venue. Additionally, Sun Life hosted a series of online games via social media, giving away over 1,000 vouchers to spread festive cheer across the city.

Adley Low, Chief Client and Marketing Officer at Sun Life Hong Kong Limited, said: “We are delighted to witness the successful conclusion of the “Sun Life ‘The Big Bounce’ World Tour – Hong Kong”, as this event reflects our purpose to help Clients live healthier lives. The enthusiastic response this year reflects not only the joy this event brought to the public, but also how much Hong Kong families truly value active and healthy living. As Sun Life approaches its 135th anniversary in Hong Kong next year, we will continue to bring more innovative and meaningful community initiatives that allow people to embrace healthy lifestyles in a relaxed and enjoyable way.”

For more highlights of the “Sun Life ‘The Big Bounce’ World Tour – Hong Kong,” please visit:
https://sunlife.co/b72002

About Sun Life

Sun Life is a leading international financial services organisation providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including: Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, Mainland China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2025, Sun Life had total assets under management of $1.60 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited (incorporated in Bermuda with limited liability) is a wholly-owned subsidiary of Sun Life Assurance Company of Canada and operates in Hong Kong.

• Demonstrates effectiveness comparable to the global standard Oka strain vaccine

YONGIN, South Korea, March 11, 2026 /PRNewswire/ — GC Biopharma(006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that a review paper comprehensively analyzing the safety and immunogenicity of its independently developed varicella vaccine strain, ‘MAV/06’, has been published in the ‘Human Vaccines & Therapeutics’, a prestigious SCIE-indexed journal.

GC Biopharma and researchers from Ajou University, and Sungkyunkwan University jointly participated in the publication of this paper. The research team systematically analyzed more than 40 studies, including clinical trial results of the MAV/06 vaccine published between 1991 and 2023, post-marketing safety reports, real-world vaccination data, and genomic analysis data.

According to the paper, the MAV/06 strain belongs genetically to the same clade (Clade 2) as the Oka-derived vaccines well-known as the global standard, yet it shows distinguished feature from the wild-type virus, thereby proving its safety as a vaccine.

In addition, MAV/06 was confirmed to induce a broad immune response not only against Clade 2 but also against Clades 1, 3, 5, and wild-type Clade 2 viruses. This signifies that GC Biopharma’s varicella vaccine can provide extensive protection against various varicella virus mutations appearing worldwide.

Furthermore, results from numerous clinical trials, including infants and immunocompromised patients, showed that the rate of neutralizing antibodies generated in the body after vaccination with the MAV/06-based varicella vaccine reached 99-100%, with antibody persistence similar to that of the Oka strain vaccine.

The analysis of real-world data accumulated over 30 years showed that the incidence of adverse events for the MAV/06-based varicella vaccine was at a level of 0.41 to 0.57 cases per 100,000 doses, which is lower than that of major global vaccines.

Notably, ‘BARYCELA Inj.’, GC Biopharma’s second varicella vaccine, is the world’s first varicella vaccine to use no antibiotics in its manufacturing process, fundamentally eliminating the possibility of adverse reactions derived from antibiotics such as Kanamycin, Neomycin, and Erythromycin.

MAV/06-based varicella vaccines have been supplied to over 20 countries more than 30 million doses to date. Also, BARYCELA Inj. obtained World Health Organization (WHO) Pre-Qualification (PQ) certification in 2023, securing competitiveness in the global public procurement market. Recently, the scope of its utilization in the global market is expected to expand with the WHO officially recognizing interchangeability with Oka strain vaccines.

“This review paper is significant in that it academically compiles the safety and effectiveness that the Korean varicella vaccine has proven in the global market over the past 30 years,” said Bong-kyoo Choi, Head of the AI&Data Science Center at GC Biopharma. “We will continue to contribute to promoting the health of children worldwide, including in countries with low vaccine accessibility.”

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo^®(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/

This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

GC Biopharma Contacts (Media)

Sohee Kim
shkim20@gccorp.com

Yelin Jun
yelin@gccorp.com

Yoonjae Na
yjy6520@gccorp.com

HONG KONG, March 11, 2026 /PRNewswire/ — GAC’s overseas markets saw strong growth early this year: Asia-Pacific sales rose 130% YoY in Jan-Feb, with gains in Singapore, Indonesia, and the Philippines. In Thailand, January new registrations surged 438% YoY and 234% MoM.

Among them, AION delivered a remarkable performance in Hong Kong. According to the latest registration data for new electric private cars released by the Hong Kong Transport Department in February 2026, AION has surged to become the third best-selling EV brand overall in Hong Kong and ranks second among Chinese brands, demonstrating strong growth momentum and deep market recognition.

This achievement marks the successful implementation of market strategy. Since launching the “Hong Kong ACTION” strategy in 2025, AION has established a comprehensive presence across products, channels, services, energy systems, and mobility ecosystems, deeply cultivating and serving the Hong Kong market.

After breaking into the market’s TOP 3 multiple times in 2025, the brand has once again validated the competitiveness and reputation of “Intelligent Manufacturing in China” with solid sales data at the beginning of 2026.

As a top-two Chinese brand in EV sales, AION has won the trust of Hong Kong consumers through precise product positioning and excellent quality. Currently, its four main models—AION V, AION UT, AION ES, and HYPTEC HT—are meeting diverse user needs with their unique advantages.

This honor received by AION in Hong Kong is a significant outcome of the “Hong Kong ACTION” strategy’s implementation. Guided by the “One GAC 2.0” globalization strategy, Hong Kong, serving as the “bridgehead” for GAC’s global strategy, is being accelerated into another benchmark overseas market. This represents not only quantitative growth but also a “qualitative leap” achieved by pursuing a path of high-quality international expansion with GAC characteristics.

Looking ahead, GAC will uphold its brand values of “quality leadership, technological innovation” and its brand philosophy of “service first, customer foremost.” Taking Hong Kong as a model, we will adhere to the principle of “In Local For Local,” striving to become a creator of low-carbon, green and intelligent mobility value for a better life.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

TOKYO, March 11, 2026 /PRNewswire/ — ARBOR Technology, a global leader in industrial computing, is proud to announce its participation in Japan IT Week 2026, held from April 8-10 at Tokyo Big Sight. Under the theme “Reliable Edge AI: The Core of Next-Gen Manufacturing” ARBOR will present its latest breakthroughs in mobile computing and edge automation at West Hall 4, Booth W25-6.

Guided by the new vision, “From Edge to Action,” ARBOR is committed to bridging the gap between raw data and real-time operational excellence. By providing high-performance, rugged hardware, ARBOR enables manufacturers to transform edge intelligence into immediate, impactful results.

Featured Solution Highlights:

• Advanced Mobile Payment & Enterprise Management Solution

  This solution leverages the Ruby 10 rugged tablet as a secure, mobile hub. Featuring integrated front-screen NFC and EMVCo LoA certification, it offers a reliable platform for secure transactions. Certified by 42Gears’ SureMDM, it provides IT administrators with centralized control in an IP65-rated mobile form factor.

• Industrial Automation & Field Control Solution

  A high-performance Windows-based platform centered on the ART10-ECA rugged tablet. It enables seamless integration with existing MES and ERP systems, providing real-time data visualization. Built to withstand industrial rigors, it features an IP65-rated seal and 1m drop resistance.

• Revolutionizing Healthcare with Edge AI HPC

  The EdgeX-6000 delivers server-grade power to the clinical edge. Powered by AMD EPYC™ Embedded 8004 processors with up to 64 cores, this high-throughput platform turns complex medical data into actionable diagnostic results.

• High-Performance AI Supercomputer Featuring NVIDIA Blackwell

  The AEC-8000 is an industrial-grade powerhouse harnessing the NVIDIA Blackwell GPU architecture. Delivering 2070 FP4 TFLOPS, it is optimized for massive-scale video analytics, processing over 64 high-definition streams for real-time intelligence.

“Our vision, ‘From Edge to Action,’ reflects our mission to empower customers with the tools they need to make smarter, faster decisions” said Ivan Huang, Vice President of APAC at ARBOR Technology. “With the Ruby 10 and ART10-ECA, we are making autonomous, high-efficiency manufacturing a reality today.”

Visit ARBOR Technology at West Hall 4, Booth W25-6 to experience how we turn Edge intelligence into Action.

For more information, please visit: https://www.arbor-technology.com/en/new/ARBOR-Technology-Accelerates-Industrial-Transformation-with-Reliable-Edge-AI-at-Japan-IT-Week-2026

CONTACT: Rex Pan, rexpan@arbor.com.tw

ROME, March 11, 2026 /PRNewswire/ — Haier Biomedical recently convened its European Partner Summit in Rome under the theme “Advancing Together – Sharing the Future of Biomedical Innovation,” which brought together 37 regional partners and industry leaders from 23 European countries to outline its long-term commitment to Europe and unveil a broadened laboratory solutions portfolio, marking a strategic upgrade of its brand portfolio. New strategy shifts toward scenario-based, application-driven solutions, while sharing its long-term plan to deepen localization in Europe and deliver more comprehensive, tailored services and support across the region.

At the summit, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the Company’s global vision to achieve over 50% of global revenue from international markets by 2027 and over 50% revenue contribution beyond refrigeration by 2028. He emphasized that Europe remains a strategic priority within the company’s globalization roadmap, which underscores the “In Europe, for Europe” localization principle of delivering products, services, and support tailored for regional regulatory standards, customer expectations, and application needs.

Outlining the 2026 European strategy, Semir Selimovic, director of North, Central & Eastern Europe of Haier Biomedical Europe, highlighted continued investment in local sales, service, and product expertise to strengthen responsiveness and execution across key markets. Europe has become one of Haier Biomedical’s fastest-growing international regions, and this is supported by expanding local teams and a steadily broadening product portfolio.

Expanding from freezers to full solutions

Among the newly introduced products, the Plasma Apheresis System XJ-III drew particular attention. The system has obtained EU MDR certification, which marks a significant milestone in meeting Europe’s stringent regulatory requirements and strengthens Haier Biomedical’s position in blood and plasma technology. Across Europe, Haier Biomedical’s CO₂ incubators, centrifuges, biosafety cabinets, and cold storage lines continue to gain market share, supported by energy-efficient technologies and compliance with regional certification standards. The product evolution presented in Rome demonstrates a move toward unlocking a full portfolio capable of supporting laboratories, hospitals, and life science institutions with end-to-end solutions.

Automation and intelligent blood management as growth engines

Daniele Pericolini, European Automation Solution Specialist of Haier Biomedical, outlined the Company’s strategy to drive future growth through laboratory automation and intelligent blood management systems. Haier Biomedical’s automated biobank solutions integrate RFID-enabled ultra-low temperature storage, modular automation platforms, and liquid nitrogen systems to enhance sample traceability and operational efficiency. By addressing challenges such as sample integrity, temperature tracking, and high-density storage, the Company has positioned itself within Europe’s growing demand for advanced biobanking infrastructure.

Additionally, the U-Blood intelligent blood management system represents a shift from traditional cold storage to real-time connected blood supply chain management. Designed to reduce wastage, improve traceability, and support round-the-clock transfusion workflows, the solution aligns with Europe’s increasing focus on safety, digitization, and zero-waste healthcare initiatives.

European customer recognition and brand alignment

The summit also featured success stories from four European partners representing Germany, Slovakia, France, and Denmark, which highlighted strong local validation of Haier Biomedical’s solutions. In France, long-term partner showcased the jointly developed biosafety cabinet adapted to French standards, with over 230 units deployed across over 100 customers. In Denmark, Haier Biomedical partner shared its ultra-low temperature freezer success through public tenders and ongoing expansion into additional product categories. In Slovenia, large-scale pharmaceutical installations reinforced the Company’s capabilities in managing complex, multi-unit projects. Partners from Central Europe also emphasized reliability, regulatory compliance, and after-sales support as key differentiators.

Strong international growth performance in 2025

Haier Biomedical’s expanding European footprint is supported by a solid financial performance. In 2025, the Company reported revenue exceeding RMB 2.3 billion, with international revenue reaching RMB 840 million, which accounts for over 36% of total revenue and reflects continued global expansion.

Europe recorded double-digit growth, which contributed to a large portion of overall international revenue growth. The Company’s AI-driven and automation-related solutions contributed approximately 15% of total revenue in 2025, which signalled accelerating technology-driven transformation. These results reflect a broader shift from hardware exports toward localized solution delivery supported by regional teams and certifications across over 18 countries.

As the European Partner Summit concluded, Haier Biomedical reaffirmed its commitment to strengthening localized operations, expanding automation and life science solutions, and advancing collaborative growth with partners. Through a combination of global innovation capabilities and local execution in Europe, the Company aims to further consolidate its position as a trusted life science solutions provider in 2026 and beyond.

For more information, please visit https://www.haiermedical.com/.

HSINCHU, March 11, 2026 /PRNewswire/ — At the satellite industry’s premier global trade show, Satellite 2026 in Washington, D.C., YTTEK, a leading provider of wireless communication solutions in Taiwan, will make its first public debut of a fully integrated end-to-end satellite communications (SATCOM) architecture spanning ground stations, satellite payloads, and automotive user terminals. The debut is more than a product showcase. It highlights Taiwan’s evolution in the global satellite supply chain—from component manufacturing to full-system SATCOM integration.

Ground segment: National space agency-validated, mission-proven performance
YTTEK has built its satellite communications expertise through long-term collaboration with the Taiwan Space Agency (TASA). Its satellite ground station modem has been mission-proven, successfully receiving and decoding signals from TASA’s Formosat-5 and NASA’s Landsat-8 and Landsat-9 satellites. These accomplishments position YTTEK among the few Asian firms with verified, national-level satellite communications credentials.

Space segment: Targeting 2027 launch for communication payload
Building on its ground-proven systems, YTTEK will showcase a high-throughput, flexible satellite communication payload designed for CubeSats and Low Earth Orbit (LEO) satellites. The payload features a Software-Defined Radio (SDR) architecture capable of supporting multiple protocols, overcoming the limitations of traditional fixed hardware. Having successfully passed national space qualification testing, it has now entered the engineering verification phase, with a targeted launch in 2027 to secure flight heritage.

Automotive Segment: Redefining satellite connectivity for smart mobility
Expanding into smart mobility, YTTEK has partnered with Tier-1 supplier AUO Mobility Solutions Corporation to co-develop a next-generation automotive satellite User Terminal (UT). The solution combines AUO’s roof-integrated transparent glass antenna with YTTEK’s satellite communication system for user terminals. Featuring a millisecond-response Antenna Control Unit (ACU) built for seamless modem integration, YTTEK’s system ensures precise satellite tracking and uninterrupted connectivity, even at high speeds across complex terrains.

From integration to complete systems
“As global LEO deployments accelerate, competition is shifting from individual components to system-level integration,” said Jiangson Chen, CEO of YTTEK. “Our goal is to build a complete satellite communications solution—from ground to satellite to vehicle.”

At Satellite 2026, YTTEK aims to deepen collaboration with global aerospace leaders and system integrators, leveraging its end-to-end integration capabilities to strengthen Taiwan’s strategic role in the global LEO satellite ecosystem.

For more information, visit:
https://yttek.com/satellite-2026-mission-proven-tasa-validated-satcom/

About YTTEK Technology
YTTEK, a leader in Software-Defined Radio (SDR), delivers cutting-edge wireless communication solutions for satellite communications, defense UAV and academic applications. We are dedicated to offering proven, reliable, and integrated communication solutions, helping customers accelerate product development and ensure exceptional performance.